JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NEUROCRINE BIOSCIENCES INC
Explicit Guidance:
- FY2027 Ingreza Revenue: Expected to grow as a "net grower" in both volume and revenue, driven by double-digit volume growth offsetting single-to-mid-single-digit price concessions (statutory rebates and access concessions).
- FY2028 Ingreza Revenue: Projected to be another "low single-digit price decline year" while maintaining double-digit volume growth, positioning the product for long-term growth through 2038.
- FY2029 IRA Impact: Anticipated to be a "manageable" financial year characterized by a "divot" rather than a "cliff" in revenue due to price negotiations (25–34% discount off non-FAMP), with recovery and growth expected into the 2030s.
- Revenue Baseline: Ingreza sales annualized at ~$800M (Q3); Chronicity annualized at ~$850M; Company total sales annualized at ~$4.5B (Q3 run rate).
- Revenue Mix: Approximately 30% of revenue expected to come from non-Ingreza medicines.
Business-Segment Outlook:
- Ingreza (Tardive Dyskinesia): Strong access maintained for 2027–2028; IP protection extends to 2038; next-generation VMAT2 molecule (890) Phase II data expected mid-2027 to inform Phase III registration and potential Long-Acting Injectable (LAI) development.
- Chronicity (Congenital Adrenal Hyperplasia): Projected to become the standard of care; market penetration expected to grow despite competition (e.g., Vertex) due to upstream HPA axis control; pediatric data expansion ongoing to treat patients from 4 months of age.
- Vicat XR (Prader-Willi Syndrome): Aiming for "good progress" in 2027; positioned as a potential long-term best-in-class medicine.
- Pipeline Readouts (2027): Multiple Phase II and Phase III data readouts scheduled:
- Otsivampator (MDD): Phase III studies.
- MDD (Otsivampator): Phase III studies.
- Diridicine (Schizophrenia): Phase III studies.
- 890 (Next-gen VMAT2): Phase II dose-finding data mid-2027.
- New Phase I starts: 6 new programs.
- New Phase II starts: 5 new programs.
Market and Competitive Outlook:
- Tardive Dyskinesia Market: Underlying market growing at mid-teens rates (~15% CAGR) driven by antipsychotic prescription volume (75M prescriptions last year, growing 3% annually); Neurocrine views this as a "two-product category" evolving into a differentiated access environment in 2027.
- Ingreza vs. Teva (Austedo): 2027 dynamics shift as Teva enters IRA with Maximum Fair Price (MFP) pulling down their effective price; Ingreza avoids IRA until 2029, securing strong access and share in the interim.
- Long-Acting Injectables (LAI): Identified as a significant unmet need for VMAT2 class (adherence issues); next-gen molecules (890) designed for higher potency, no 2D6 metabolism, and longer half-life to facilitate oral-to-LAI transition (oral first, LAI staggered).
- Chronicity vs. Competitors: Confidence that multiple market entrants will accelerate overall disease penetration; Neurocrine expects to maintain leadership via superior long-term data on ACTH/A4 reduction and pediatric efficacy.
- MDD/Otsivampator: Positioned to avoid glutamatergic surge and psychotomimetic side effects associated with ketamine by using direct AMPA positive allosteric modulation.
Macro / Industry Outlook:
- IRA (Inflation Reduction Act): 2029 is identified as the first IRA pricing negotiation window for Ingreza (small biotech exemption: 25–34% discount off non-FAMP); negotiations with CMS expected to conclude in fall following spring discussions.
- Regulatory Environment: FDA Neuropsych Division actively engaged in blinded data review for Otsivampator trials; sites intervened/retrained based on data quality oversight.
- Market Structure: Shift from a static two-product category to a dynamic era where competitor IRA status creates a differentiated access landscape for Neurocrine in 2027–2028.
Strategic Initiatives:
- R&D Productivity: 2027 marked as the most productive year in company history for R&D (6 new Phase I starts, 5 new Phase II starts).
- Next-Gen VMAT2 Development (Molecule 890): Designing for oral administration first, followed by staggered LAI development to offer a "one-stop shopping" approach (oral stabilization -> LAI maintenance).
- Pediatric Expansion: Ongoing studies to treat Congenital Adrenal Hyperplasia patients from 4 months of age to alter disease trajectory early.
- Access Strategy: Addressed access concerns for 2027–2028 to ensure net revenue growth despite price concessions; focus on maintaining high plan coverage (100% on plans).
Risks and Headwinds to Outlook:
- IRA Pricing (2029): While labeled "manageable," a "divot" in revenue is expected due to the 25–34% discount floor and statutory rebate offsets; potential "best price" implications for Medicaid require consideration.
- Competitive Entry: Future entry of competitor products (e.g., Vertex) could impact pricing or market share, though management views this as a market expansion opportunity.
- Clinical Execution: MDD trials carry inherent risks of placebo response; high variability in patient screening or site performance remains a risk (mitigated by strict site oversight and 200-patient trial sizes).
- Safety/Tolerability: Potential for QT liability (mitigated in 890) or other adverse events, though Otsivampator Phase III shows >90% rollover to open-label extension and low dropout rates.
Management Tone on the Future:
- Confidence Level: High confidence in the 2027–2028 commercial trajectory, describing the error bars as "narrowed" compared to previous years.
- Strategic Narrative: Describes 2027 as a "most important catalyst slate" in company history; emphasizes a transition from a single-product to a diversified, three-medicine company.
- Hedging: Avoids predicting "zero price impact" for 2029 but firmly rejects the "cliff" narrative; uses terms like "divot" and "manageable" to temper expectations while maintaining growth optimism.
- Operational Focus: Emphasizes rigorous clinical oversight and "learning by doing" in expanding the pipeline.
Miscellaneous:
- Financial Resources: Management cites "strong financial resources" supporting the expansion of the pipeline and commercial portfolio.
- Salesforce: Recent expansions noted as a learned strategy to increase diagnosis and patient care capture in the TD market.
- Long-term Vision: Company positioned to grow "well into the future" with IP extending to 2038 for Ingreza and a diversified pipeline driving long-term growth.
- Company
- NEUROCRINE BIOSCIENCES INC
- Keywords
- NEUROCRINE BIOSCIENCES INC